Coherus Oncology, Inc. (CHRS) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 56.0% | -41.8% | 10.7% |
| 2023 | 38.2% | -79.0% | -92.5% |
| 2022 | 66.8% | -121.7% | -138.2% |
| 2021 | 82.4% | -80.8% | -87.9% |
| 2020 | 92.1% | 32.9% | 27.8% |
Download Data
Export CHRS earnings history in CSV or JSON format
Free sign-in required to download data
Coherus Oncology, Inc. (CHRS) Earnings Overview
As of February 28, 2026, Coherus Oncology, Inc. (CHRS) reported trailing twelve-month net income of $155M, reflecting +1.1% year-over-year growth. The company earned $1.33 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, CHRS's 5-year EPS compound annual growth rate (CAGR) stands at -27.3%, signaling declining earnings. The company achieved its highest annual net income of $132M in fiscal 2020.
Coherus Oncology, Inc. maintains positive profitability with a gross margin of 0.6%, operating margin of -0.4%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), CHRS has comparable earnings metrics. Compare CHRS vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $29M | +112.0% | -$112M | $0.25 | 10.7% | -41.8% |
| 2023 | -$238M | +18.5% | -$203M | $-2.53 | -92.5% | -79.0% |
| 2022 | -$292M | -1.6% | -$257M | $-3.76 | -138.2% | -121.7% |
| 2021 | -$287M | -317.1% | -$264M | $-3.81 | -87.9% | -80.8% |
| 2020 | $132M | +47.2% | $156M | $1.62 | 27.8% | 32.9% |
| 2019 | $90M | +142.9% | $108M | $1.23 | 25.2% | 30.3% |
| 2018 | -$209M | +12.1% | -$204M | $-3.22 | -13453.7% | -13137.3% |
| 2017 | -$238M | -87.0% | -$232M | $-4.48 | -15306.6% | -14918.8% |
| 2016 | -$127M | +43.0% | -$116M | $-3.04 | -67.0% | -61.0% |
| 2015 | -$223M | -156.2% | -$219M | $-6.01 | -743.2% | -729.2% |
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CHRS vs AGIO
See how CHRS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CHRS growing earnings?
CHRS EPS of $1.33 reflects slowing growth at +1.1%, below the 5-year CAGR of -27.3%. TTM net income is $155M. Expansion rate has moderated.
What are CHRS's profit margins?
Coherus Oncology, Inc. net margin is +0.1%, with operating margin at -0.4%. Below-average margins reflect competitive or cost pressures.
How consistent are CHRS's earnings?
CHRS earnings data spans 2012-2024. The current earnings trend is +1.1% YoY. Historical data enables comparison across business cycles.